US BIOTECH PHASE II/III SHORTLIST

Which CRO fits your Phase II/III clinical trial?

Compare published phase coverage, therapeutic focus, and delivery models across 16 shortlisted CROs before sending an RFI. Study pricing was not established from reviewed service pages and must be requested per study.

CROPhase scopeTherapeutic focusDelivery model
IQVIA
Phase IIb/III TrialsVendor service page claim; this title establishes a marketed Phase IIb/III offering only, not study-specific experience, performance or suitability.Source ↗ · RecordIncludes oncology/hematology, CNS, rare disease, obesity and cell/gene therapy.Company-wide claim; ask for matching study references and a named available team.Source & dateNot detailed on reviewed page Why unknown
ICON plc
Phase 2–3 clinical operationsCompany-wide claim; ask for matching study references and a named available team.Source & dateCardio-metabolic, oncology/hematology, infection, neurology/psychiatry, rare disease, respiratory and biosimilars.Company-wide claim; ask for matching study references and a named available team.Source & dateTraditional, decentralized or hybrid trial deliveryCompany-wide claim; ask for matching study references and a named available team.Source & date
Medpace
all phases of development (including wholly-owned Phase I Unit)Vendor homepage claim; does not establish indication-specific trial counts or study outcomes.Source ↗ · RecordIncludes oncology/hematology, endocrine/metabolic, neuroscience, immunology and rare disease.Company-wide claim; ask for matching study references and a named available team.Source & datefull-service, single-vendor outsourcing with wholly-owned Central Labs, Bioanalytical Lab, Imaging Core Lab, ECG Core Lab and CTMSVendor-stated full-service model; FSP availability not offered/stated on homepage.Source ↗ · Record
Parexel
Phase IIb-IV clinical trialsSource ↗ · RecordGeneral medicine, infectious disease and vaccines, immunology, neuroscienceVendor-listed therapeutic areas on integrated clinical development page; additional therapeutic areas may appear on separate pages.Source ↗ · RecordIntegrated clinical development with Site Alliance Network, decentralized trial (DCT) elements, regulatory strategy, clinical logistics, pharmacovigilanceVendor service statement; protocol-level site availability requires verification.Source ↗ · Record
Syneos Health
all phases including Early Phase, Phase II-IV and Real World EvidenceSource ↗ · Recordoncology and hematology, neuroscience, rare disease, dermatologyVendor claim; self-reported ~70% biotech customer portfolio.Source ↗ · RecordFull-service outsourcing (FSO) and Functional Service Provider (FSP 360)Source ↗ · Record
Fortrea
Not stated on reviewed page Why unknownNot listed on reviewed page Why unknownfull service and FSP clinical development with FDA Diversity Action Plan supportVendor service statement; does not specify individual trial phase exclusions.Source ↗ · Record
Thermo Fisher Scientific, PPD clinical services
early development, all phases of clinical development, peri- and post-approvalSource ↗ · RecordNot listed on reviewed page Why unknownfull-service partnerships, functional service partnerships (FSP), and comprehensive laboratory servicesSource ↗ · Record
Labcorp Drug Development
Not stated on reviewed page Why unknownNot listed on reviewed page Why unknownnonclinical development, central lab services (100+ countries), and companion diagnostics (distinct lab/enablement focus)Current biopharma page foregrounds laboratory, nonclinical, and CDx services rather than standalone full-service CRO trial management.Source ↗ · Record
Worldwide Clinical Trials
Phase I-IIa, Phase II-IV (specializing in Phase IIb-IV peri-approval), RWE, and Transition StudiesVendor capability claim; specific therapeutic indications sit on separate subpages.Source ↗ · RecordNot listed on reviewed page Why unknownPhase I-IV trial execution, RWE, and Transition Studies (mid-trial rescue)Vendor markets mid-trial transition/rescue capability.Source ↗ · Record
Precision for Medicine
Early Phase (first-in-human through Phase 2a) and Late Phase (Phase 2b-4 pivotal)Source ↗ · RecordOncology & immuno-oncology (stated 76% of trials), rare & orphan diseases (stated 67% of trials), autoimmune, cell/gene therapyVendor self-reported trial percentages; percentages overlap because trials can be both oncology and rare disease.Source ↗ · RecordFull-service CRO and FSP services with integrated translational/biomarker science and Precision labsSource ↗ · Record
Veristat
complex Phase I-III clinical developmentSource ↗ · Recordrare disease trial delivery and complex specialty programsVendor lists rare disease and natural history trial delivery; other indications not enumerated on page.Source ↗ · Recordspecialty CRO combining regulatory advisory, biostatistics/InStat, clinical operations, DCT, and clinical trial rescueSource ↗ · Record
Premier Research
Not stated on reviewed page Why unknownNot listed on reviewed page Why unknownglobal full-service CRO with clinical research and consulting across the development lifecycleHomepage statement only; therapeutic areas and specific trial phases sit on linked subpages not captured here.Source ↗ · Record
Indero
early and late phase clinical trialsSource ↗ · Recorddual-focus dermatology (30+ indications) and rheumatology (20+ indications)Specialty dual-focus CRO; North America CRU operates as Innovaderm.Source ↗ · Recorddual-focus specialty CRO (formerly Innovaderm) with affiliated clinical research unit for North America/global trialsHeadquartered in Montreal, Canada with North America trial capabilities.Source ↗ · Record
Kapadi
Not stated on reviewed page Why unknownoncology (solid and liquid malignancies, immuno-oncology) and cell & gene therapies (common and rare indications)Vendor specialty positioning; notes partnership/historic connection to Moffitt Cancer Center.Source ↗ · Recordglobal full service and FSP oncology/CGT CROVendor service statement; specific trial phases not enumerated on homepage.Source ↗ · Record
PharPoint
Phase II-IV clinical trialsSource ↗ · RecordNot listed on reviewed page Why unknownFull-service Phase II-IV CRO covering site feasibility, clinical operations, data management, and biostatisticsVendor service statement; notes APAC CRO partner network alongside US work.Source ↗ · Record
Proxima CRO
Not stated on reviewed page Why unknownNot listed on reviewed page Why unknownBiotech and MedTech CRO covering drugs, medical devices, and diagnostics (regulatory strategy, quality systems, clinical trials, RWE)Mixed MedTech and biotech scope; confirm pure-biotech Phase II/III drug trial depth separately.Source ↗ · Record
Open the RFI question list →

All cells above come from dated vendor service statements, not trial outcomes or named team capacity. Shared limits & why some fields are unknown.